AGIO Description — Agios Pharmaceuticals Inc

Agios Pharmaceuticals is a biopharmaceutical company focused on improving patients' lives in the field of cellular metabolism and adjacent areas of biology, with the goal of creating molecule medicines for genetically defined diseases (GDD). The lead product in its GDD, portfolio, PYRUKYND® (mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the potential treatment of hemolytic anemias. Co. is evaluating PYRUKYND® for the treatment of a- and B-thalassemia and sickle cell disease (SCD). Co. is also developing AG-946, a PK activator, for the potential treatment of hemolytic anemias and other indications, including SCD.

Company Name: 
Agios Pharmaceuticals Inc
Drugs & Pharmaceuticals
Number of ETFs Holding AGIO: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   AGIO Weight   AGIO Amount 
 XBI   0.65%   $42,589,051         
 FBT   2.78%   $39,592,248         
 VTI   0.00%   $36,702,630         
 VB   0.03%   $30,611,336         
 IWM   0.05%   $26,403,709         
 VXF   0.02%   $15,787,510         
 IWN   0.11%   $11,894,979         
 VBR   0.02%   $10,807,319         
 VBK   0.03%   $8,860,230         
 VHT   0.02%   $3,705,582         
List of all 32 ETFs holding AGIO »
Quotes delayed 20 minutes

Email EnvelopeFree AGIO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Buy (3.00 out of 4)
33rd percentile
(ranked lower than approx. 67% of all stocks covered)

Analysts Forecast:
AGIO Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding AGIO | Agios Pharmaceuticals Inc | ETF Channel |

Copyright © 2010 - 2023, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.